ART Advanced Research to test SoftScan in treatment monitoring

By Elaine Rigoli

Tampa, Fla., July 13 - ART Advanced Research Technologies, Inc. has obtained authorization from Health Canada's Therapeutic Products Directorate to begin a pilot study to evaluate the effectiveness of the SoftScan optical breast imaging system in treatment monitoring.

The company said this may extend the clinical value of SoftScan beyond its role in breast cancer detection and diagnosis and into breast cancer treatment.

Preliminary data suggest that SoftScan is effective at showing tumor response to treatments. This technology could potentially allow for a patient to be scanned after a few rounds of powerful chemotherapy drugs to see whether the tumor is shrinking, instead of waiting for the standard 12-week increments, officials noted.

Montreal-based ART develops molecular-imaging products for the health care and pharmaceutical industries.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.